{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:17:37Z","timestamp":1778581057207,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018557","name":"Science and Technology Project of Nantong City","doi-asserted-by":"publisher","award":["JCZ19022"],"award-info":[{"award-number":["JCZ19022"]}],"id":[{"id":"10.13039\/501100018557","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bbr.2021.113535","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T07:40:50Z","timestamp":1629272450000},"page":"113535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Promoting the hippocampal PPAR\u03b1 expression participates in the antidepressant mechanism of reboxetine, a selective norepinephrine reuptake inhibitor"],"prefix":"10.1016","volume":"416","author":[{"given":"Shangyan","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaoni","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1643-2126","authenticated-orcid":false,"given":"Weihua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2021.113535_bib0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuroscience.2015.05.053","article-title":"Pathogenesis of depression: insights from human and rodent studies","volume":"321","author":"M\u00e9nard","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2021.113535_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2015.17.2\/dionescu","article-title":"Pharmacological approaches to the challenge of treatment-resistant depression","volume":"17","author":"Ionescu","year":"2015","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.bbr.2021.113535_bib0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-981-32-9271-0_8","article-title":"Advance in stress for depressive disorder","volume":"1180","author":"Ding","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bbr.2021.113535_bib0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12199-008-0073-6","article-title":"Molecular epidemiology of major depressive disorder","volume":"14","author":"Kiyohara","year":"2009","journal-title":"Environ. Health Prev. Med."},{"key":"10.1016\/j.bbr.2021.113535_bib0025","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2174\/138161209788168001","article-title":"Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today","volume":"15","author":"L\u00f3pez-Mu\u00f1oz","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbr.2021.113535_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00441-018-2978-8","article-title":"Monoaminergic system and depression","volume":"377","author":"Perez-Caballero","year":"2019","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bbr.2021.113535_bib0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ejn.14547","article-title":"Neurobiology of resilience in depression: immune and vascular insights from human and animal studies","volume":"53","author":"Dudek","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2021.113535_bib0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0705113","article-title":"RXR activators molecular signalling: involvement of a PPAR alpha-dependent pathway in the liver and kidney, evidence for an alternative pathway in the heart","volume":"138","author":"Ouamrane","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113535_bib0045","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s11064-020-02993-5","article-title":"The novel role of PPAR Alpha in the brain: promising target in therapy of Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"45","author":"W\u00f3jtowicz","year":"2020","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bbr.2021.113535_bib0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1365-2362.2010.02318.x","article-title":"Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart","volume":"40","author":"Lee","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bbr.2021.113535_bib0055","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.semcdb.2012.01.003","article-title":"PPARs: fatty acid sensors controlling metabolism","volume":"23","author":"Poulsen","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bbr.2021.113535_bib0060","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbr.2021.113535_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113323","article-title":"Neurovascular protection by peroxisome proliferator-activated receptor alpha in ischemic stroke","volume":"331","author":"Boese","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2021.113535_bib0070","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1111\/bph.14346","article-title":"Hippocampal PPARalpha is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice","volume":"175","author":"Song","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113535_bib0075","first-page":"4","article-title":"Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review","volume":"14","author":"Burrows","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbr.2021.113535_bib0080","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1345\/aph.19335","article-title":"Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression","volume":"34","author":"Scates","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bbr.2021.113535_bib0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1527-3458.2004.tb00002.x","article-title":"The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile","volume":"10","author":"Haj\u00f3s","year":"2004","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.bbr.2021.113535_bib0090","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0028-3908(00)00164-7","article-title":"Effect of reboxetine treatment on brain cAMP- and calcium\/calmodulin-dependent protein kinases","volume":"40","author":"Mori","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2021.113535_bib0095","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1017\/S1461145713000370","article-title":"Hippocampal and prefrontal dopamine D1\/5 receptor involvement in the memory-enhancing effect of reboxetine","volume":"16","author":"De Bundel","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2021.113535_bib0100","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1007\/s12035-019-01695-6","article-title":"Reboxetine treatment reduces neuroinflammation and neurodegeneration in the 5xFAD mouse model of Alzheimer\u2019s disease: role of CCL2","volume":"56","author":"Guti\u00e9rrez","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bbr.2021.113535_bib0105","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113535_bib0110","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1111\/bph.12955","article-title":"Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP","volume":"172","author":"McGrath","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113535_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2015.10.006","article-title":"Effects of lobeline and reboxetine, fluoxetine, or bupropion combination on depression-like behaviors in mice","volume":"139","author":"Roni","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2021.113535_bib0120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bph.13668","article-title":"Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway","volume":"174","author":"Jiang","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbr.2021.113535_bib0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.brainresbull.2019.08.016","article-title":"Hippocampal PPARalpha is involved in the antidepressant-like effects of venlafaxine in mice","volume":"153","author":"Chen","year":"2019","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbr.2021.113535_bib0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainresbull.2020.02.010","article-title":"Hippocampal overexpression of chordin protects against the chronic social defeat stress-induced depressive-like effects in mice","volume":"158","author":"Wang","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbr.2021.113535_bib0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.brainresbull.2020.08.028","article-title":"Imipramine exerts antidepressant-like effects in chronic stress models of depression by promoting CRTC1 expression in the mPFC","volume":"164","author":"Wang","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbr.2021.113535_bib0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review","volume":"13","author":"Grygiel-G\u00f3rniak","year":"2014","journal-title":"Nutr. J."},{"key":"10.1016\/j.bbr.2021.113535_bib0145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1517\/14728222.2012.715633","article-title":"PPARalpha as a therapeutic target in inflammation-associated diseases","volume":"16","author":"Gervois","year":"2012","journal-title":"Exp. Opin. Ther. Targets"},{"key":"10.1016\/j.bbr.2021.113535_bib0150","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbr.2021.113535_bib0155","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1042\/BST0341341","article-title":"PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases","volume":"34","author":"Bordet","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbr.2021.113535_bib0160","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.2174\/0929867321666140303143455","article-title":"Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARalpha) and its lipid ligands","volume":"21","author":"Fidaleo","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbr.2021.113535_bib0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2174\/1567205014666170505094549","article-title":"Targeting PPARalpha in Alzheimer\u2019s disease","volume":"15","author":"D\u2019Orio","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bbr.2021.113535_bib0170","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00213-014-3802-0","article-title":"WY14643 produces anti-depressant-like effects in mice via the BDNF signaling pathway","volume":"232","author":"Jiang","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.bbr.2021.113535_bib0175","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0269881118762072","article-title":"Gemfibrozil has antidepressant effects in mice: involvement of the hippocampal brain-derived neurotrophic factor system","volume":"32","author":"Ni","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bbr.2021.113535_bib0180","article-title":"Chronic social defeat stress mouse model: current view on its behavioral deficits and modifications","author":"Wang","year":"2021","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.bbr.2021.113535_bib0185","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.celrep.2013.07.028","article-title":"Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor alpha","volume":"4","author":"Roy","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbr.2021.113535_bib0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiology of depression","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2021.113535_bib0195","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1523\/JNEUROSCI.0367-19.2019","article-title":"CREB family transcription factors are major mediators of BDNF transcriptional autoregulation in cortical neurons","volume":"40","author":"Esvald","year":"2020","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2021.113535_bib0200","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.biopsych.2005.11.003","article-title":"The role of CREB in depression and antidepressant treatment","volume":"59","author":"Blendy","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbr.2021.113535_bib0205","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","article-title":"BDNF - a key transducer of antidepressant effects","volume":"102","author":"Bj\u00f6rkholm","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2021.113535_bib0210","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1440-1681.12746","article-title":"Changes in PPAR\u03b4 expression in a rat model of stress-induced depression","volume":"44","author":"Liu","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.bbr.2021.113535_bib0215","article-title":"Hippocampal PPAR\u03b4 overexpression or activation represses stress-induced depressive behaviors and enhances neurogenesis","volume":"19","author":"Ji","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2021.113535_bib0220","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12974-016-0728-y","article-title":"The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPAR\u03b3-mediated alteration of microglial activation phenotypes","volume":"13","author":"Zhao","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.bbr.2021.113535_bib0225","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.lfs.2018.04.057","article-title":"The antidepressant effects of rosiglitazone on rats with depression induced by neuropathic pain","volume":"203","author":"Zong","year":"2018","journal-title":"Life Sci."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643282100423X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643282100423X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:30:49Z","timestamp":1759066249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016643282100423X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":45,"alternative-id":["S016643282100423X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2021.113535","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promoting the hippocampal PPAR\u03b1 expression participates in the antidepressant mechanism of reboxetine, a selective norepinephrine reuptake inhibitor","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2021.113535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113535"}}